TIAP portfolio company Notch Therapeutics has announced one of the largest Series A financing rounds in the history of Canadian biotech. We are proud to say that we were there from the start in 2017 when TIAP received the technology disclosure from Dr. Zuniga-Pflucker via our Member, Sunnybrook Health Sciences Centre, and then again when we teamed up with CCRM and Dr. Peter Zandstra of University of Toronto, another one of our Members. TIAP was an early seed investor and acknowledges the recent additional support received for Notch thanks to our grant under the Federal Economic Development Agency for Southern Ontario’s Regional Innovation Ecosystem program (FedDev Ontario). We have worked closely with our partners at CCRM and Lumira Ventures on this technology as well as our strategic partner, Allogene, a leader in cell therapy.
February 10, 2021